Sirnaomics Raises $10 Million in Series B Funding Led by Hong Kong Firm

Sirnaomics, a Maryland developer of RNAi therapeutics, closed a $10 million Series B financing, led by Hong Kong-based venture fund, Value Measured Investment Limited. Sirnaomics said the capital will support a US Phase I trial of its lead candidate, STP705, an anti-fibrosis therapeutic. STP705 is expected to start trials in patients with hypertrophied scar tissue in 2H of 2016. In January of this year, Sirnaomics' China partner, Guangzhou Xiangxue Pharma filed to start a similar China trial. More details.... Stock Symbol: (SZE: 300147) Share this with colleagues: // //